TOMi Masterclass

TOMi translates knowledge about tailor-made therapy into practical use. By using real-life patient stories, we traverse the patient care path together. What are the challenges in the field of personalise medicine and how does the patient reap the benefits of healthcare innovations as quickly as possible for a better quality of life?

Register for our masterclass today, join our initiative and be inspired to implement personalised medicine in practice.


Half a day: 4 hours, including starting up and rounding up


Agri & Food Plaza – Onderwijsboulevard 225 – 5223 DE Den Bosch


  • February 03, 2021 – 8:00 a.m. till 11:00 a.m.
  • March 25, 2021 – 4:00 p.m. to 7:00 p.m.
  • April 07, 2021 – 8:00 a.m. till 11:00 a.m.
  • May 25, 2021 – 8:00 a.m. till 11:00 a.m.
  • June 23 – 8:00 a.m. till 11:00 a.m.

Return day: Thursday afternoon 19 November.


The TOM-i masterclass is intended for professionals working in the healthcare sector. There are also master classes aimed at patients, please contact us if you are interested.

The masterclass takes place when we have reached the minimum of 4 participants. The maximum number of participants is 8.


Attending the masterclass costs €495.00 p.p., including VAT – catering and teaching materials. For in-company masterclasses and custom solutions, contact us on: 073-20 32 021 or

Participate in a Masterclass

Registration form for the TOMi Masterclass

TOMi Terugkomdag

On November 19, TOMi organized the annual TOMi Terugkomdag. The starting point of this day was the approach of TOMi projects, that they focus on therapy effects with individual patients in order to be able to predict these effects better. Our research projects are closely related to clinical practice. The current Evidence Based Medicine (EBM) approach provides a good basis for predictions and comparisons with regard to effectiveness and side effects of treatments in patient groups. However, the translation of EBM to treatment effects in the individual patient becomes more problematic the less homogeneous the studied patient group is. TOMi is investigating whether participatory research (N off One studies) can provide a solution. The following speakers delivered a key note on November 19:

Dr Martijn de Groot
Martijn is the director of the REshape Institute of the UMC Radboud and became involved in N off One research because of his work with the Quantified Self movement. With this experience and with his educational and biomedical research background, he is ideally suited to peel the complexity of N off One methodology for us down to the practical essentials such as the study design and the use of tracking devices / wearables.

Alfons Olde Loohuis
50,000-100,000 people were infected with Q fever between 2005 and 2011. To this day, patients still experience serious and diverse consequences of this infection. Alfons has been confronted with Q fever from the very first hour from his general practice in Herpen. He is still an advisor to both the Q-uestion patient association and the Q-support Foundation. In this way, he supports Q fever patients who are chronically infected or have chronic fatigue. Q-uestion has now also been asked by the Ministry of Health, Welfare and Sports to use its expertise to assist patients who have been cured of the corona infection. They also show a diversity of health complaints. Alfons is directly involved in this and will also share the extent to which parallels can be drawn between the Q fever and the Covid-19 epidemic with us.

Do you want to read more about N off one?
The article to which Martijn referred (written in collaboration with Gary Wolf) about the method of participatory research (Quantified Self, Personal Science) can be read here: A Conceptual Framework for Personal Science.

Another interesting article on this topic, with an overview of aspects surrounding real word digital data studies, can be read here: Creating Evidence from Real World Patient Digital Data.

The sequel

TOMi is now investigating the possibilities of an N off One approach in the study of the clinically diverse Q fever patient group and in the study of patients with ME / CVS.